A Phase 1-2 Study of ECI830 in People With Advanced Breast Cancer and Other Solid Tumors

Full Title

An Open-Label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination with Ribociclib and Endocrine Therapy in Patients with Advanced Hormone Receptor Positive, HER2-Negative Breast Cancer and Advanced Solid Tumors

Purpose

Researchers want to find the highest dose of ECI830 that can be given safely in people with advanced cancer. The people in this study have breast cancer or other solid tumors that have spread beyond their original location.

ECI830 targets and blocks the CDK2 protein. This protein is found on cancer cells and plays a role in cancer growth and survival. By blocking CDK2, ECI830 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have breast cancer or another solid tumor that has spread beyond its original location.
• Have cancer that keeps growing after treatment or cannot be successfully treated with standard therapies.
• Not have had prior treatment with a CDK2 inhibitor.
• Have completed prior therapies at least 4 weeks before taking ECI830.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-5145.